Pfizer

Third Quarter 2023

Earnings Highlights

$13.2B
Revenue
-41% Op Decline[1]
+10% Op Growth excl. COVID-19 products

$(0.42) Rep. Dil. Loss Per Share (LPS) | **$(0.17)** Adj. Dil. Loss Per Share[2]
Percentage change not meaningful

$2.7B
Rep. R&D Expenses
+1% Op Growth

$6.9B
Cash Dividends Returned to Shareholders Year-To-Date Q3 2023
$1.23 Per Share of Common Stock

Revenue $58.0B–$61.0B
FY 2023 Guidance[3]
$1.45–$1.65 Adj. Dil. EPS[2]



"We are encouraged by the strong performance of Pfizer's non-COVID products in the third quarter of 2023. With a significant uncertainty removed by our amended COVID-19 treatment supply agreement with the U.S. government, our expectation of additional clarification on global vaccination and treatment rates by the end of the year, and the breakthroughs continuing to emerge from our pipeline, we look forward to concluding 2023 with positive momentum that showcases Pfizer's long-term growth potential."

Albert Bourla
Chairman and Chief Executive Officer

Key Growth Drivers[4]

Primary Care	Specialty Care	Oncology
$6.3B Revenue	$3.8B Revenue	$2.9B Revenue
(60%) Op Decline	+12% Op Growth	(5%) Op Decline

- ABRYSVO™ Respiratory Syncytial Virus Vaccine
- Vyndaqel® Family[5]
- Prevnar 20® Family[6] Pneumococcal Conjugate Vaccine
- Nurtec® ODT / Vydura® 75 mg
- Oxbryta®

Pipeline Spotlights[7]

- Approved in U.S. — ABRYSVO™ Respiratory Syncytial Virus Vaccine: Prevention of respiratory syncytial virus (RSV) in infants from birth up to 6 mons. by active immunization of pregnant individuals at 32 to 36 wks. gestational age
- Approved in EU — ABRYSVO™ Respiratory Syncytial Virus Vaccine: Prevention of RSV in adults 60+ yrs. and passive protection in infants from birth up to 6 mons. through maternal immunization
- Approved in U.S. — ELREXFIO™: Treatment of relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy
- Approved in EU — Litfulo: Treatment for adults and adolescents (12+ years) with severe alopecia areata
- Approved in U.S. — BRAFTOVI® MEKTOVI®: Treatment of metastatic non-small cell lung cancer with a *BRAF* V600E mutation in adults
- Approved in U.S. — Velsipity™: Treatment of moderately to severely active ulcerative colitis in adults
- Approved in U.S. — PENBRAYA™ Meningococcal Groups A, B, C, W, and Y Vaccine: Prevention of 5 most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 yrs
- Abrilada™ adalimumab: FDA grant of interchangeable designation to biosimilar Humira[8]



>457M Patients Treated
worldwide year-to-date in Q3 2023 with our medicines and vaccines[9]

Fortifying Long-Term Growth Plans

Potential Near-Term Launches[10]
Through H1 2024, up to 18 potential launches

- 13 Launched
- 4 Approved
- 1 Not Yet Launched or Approved

Business Development Opportunities
Goal to add at least $25B of risk-adjusted revenues to 2030 top-line expectations

COVID-19 Franchise
Expect to remain multi-billion dollar revenue generators

Innovative Pipeline
Potential for additional internal revenues from pipeline >2024-2030

What's Next

Remains confident in ability to deliver operational growth and meaningful shareholder value through 2025 and beyond

- **Maintain** patient centricity
- **Scale** emerging tech platforms
- **Invest** in areas we can win
- **Foster** a culture of innovation
- **Reduce** approval development cycle times

ANTICIPATES | Non-COVID 2023 operational revenue growth of 6% to 8%[11]

Pfizer

investors.pfizer.com

Please reference Pfizer's Q3 2023 earnings release and SEC filings for additional information.

[1] Operational growth. Reference to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates.

[2] Adjusted income/(loss) and Adjusted diluted EPS/(LPS) are defined as U.S. GAAP net income/(loss) attributable to Pfizer Inc. common shareholders and Reported diluted EPS/(LPS) attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the reconciliations of certain GAAP reported to Non-GAAP Adjusted information for the third quarter and first nine months of 2023 and 2022 accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated October 31, 2023. Adjusted income/(loss) and its components and Adjusted diluted EPS/(LPS) measures are not, and should not be viewed as, substitutes for U.S. GAAP net income/(loss) and its components and diluted EPS/(LPS). See the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2022 Annual Report on Form 10-K and the Non-GAAP Financial Measure: Adjusted Income section accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated October 31, 2023 for additional information.

[3] Total company guidance. Please see Pfizer's press release issued on October 13, 2023 as well as Pfizer's Q3 2023 earnings release for additional details and assumptions regarding Pfizer's 2023 financial guidance.

[4] Q3 2023 financial performance.

[5] Vyndaqel family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the U.S. and Vynmac in Japan.

[6] Prevnar family includes revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (pediatric and adult).

[7] Pipeline updates as of October 31, 2023.

[8] Humira® is a registered trademark of AbbVie Biotechnology Ltd. Abrilada is interchangeable for the indications of use, dosage forms, strengths and routes of administration described in the prescribing information.

[9] The patients treated metric is calculated from Pfizer and third-party datasets. Figures may be limited given the coverage provided by external sources (e.g., calendar duration, geographic and product coverage). Numbers are estimates and in some cases use global volume, daily dosage and number of treatment days to facilitate calculations. Methodologies to calculate estimates may vary by product type given the nature of the product and available data. Patients taking multiple Pfizer products may be counted as multiple patients towards total. Numbers include estimated patient counts from U.S. Patient Assistance Programs, ex-U.S. access & affordability programs, product donations and Global Commercial Access Partnerships (this does not include An Accord for a Healthier World). Historical estimates may periodically be subject to revision due to restatements in the underlying data source.

[10] Reference the full set of materials in the Q3 2023 Earnings Presentation for certain information regarding potential product launches. Through H1 2024, we expect to have up to 18 new products or indications in the market – including the thirteen for which we have already begun co-promotion or commercialization in 2022 and through October 2023. All dates are preliminary, subject to change, and subject to, among other risks, assumptions and uncertainties, clinical trial, regulatory and commercial success, ACIP and MMWR publication, and availability of supply.

[11] Please see Pfizer's Q3 2023 earnings release for additional details and assumptions regarding Pfizer's 2023 financial guidance.

This document includes forward-looking statements about, among other things, Pfizer's anticipated operating and financial performance, including financial guidance and projections, product pipeline, in-line products and product candidates, product launches, revenue contributions, business plans, strategy and prospects, business development activities, including the proposed acquisition of Seagen, manufacturing and product supply, capital allocation objectives, dividends and share repurchases that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2022, and Pfizer's subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These reports are available on Pfizer's website at www.pfizer.com and on the U.S. Securities and Exchange Commission's website at www. sec. gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statements.